Spring til hovednavigation Spring til søgning Spring til hovedindhold

Anaphylaxis Clinical Care Pathway: Incorporating Intranasal Epinephrine (Adrenaline)

  • Timothy E. Dribin*
  • , Brad Sobolewski
  • , Ronna L. Campbell
  • , Paul J. Turner
  • , Lene H. Garvey
  • , Jasmeet Soar
  • , Julie Wang
  • , Marcus S. Shaker
  • , Adam T. Fox
  • , Sarayna S. McGuire
  • , Kenneth A. Michelson
  • , David Schnadower
  • , Graham Roberts
  • , Waleed Alqurashi
  • , Moshe Ben-Shoshan
  • , David C. Brousseau
  • , Dianne E. Campbell
  • , Andrew T. Clark
  • , Antoine Deschildre
  • , Katie Frith
  • Mattia Giovannini, Gideon Lack, Antonella Muraro, Mark I. Neuman, Nandinee Patel, Guillaume Pouessel, Kristina Rueter, Nicholas Sargant, Peter Smith, Susan Waserman, Gary Wing Kin Wong, Margitta Worm, Hugh A. Sampson
*Corresponding author af dette arbejde

Abstract

Health care providers across settings must be trained to manage anaphylaxis by (1) removing the offending allergen if still present; (2) positioning the patient with legs elevated, and if respiratory distress is present, allow the patient to sit upright with legs extended and elevated; (3) immediately administering epinephrine (adrenaline) intramuscularly (IM) or intranasally (IN) every 5 to 15 minutes for persistent anaphylaxis; and (4) optimizing airway, breathing, and cardiovascular (ABC) resuscitation. This may include supplemental oxygen, noninvasive or invasive positive-pressure ventilation, and intravenous fluid resuscitation. For life-threatening or refractory presentations, (5) IM/IN epinephrine should be administered every 5 minutes while addressing ABC derangements; this includes aggressive intravenous fluid resuscitation for patients in anaphylactic shock. Providers may continue IM or IN epinephrine or switch to the other, as both routes are considered equally efficacious based on pharmacokinetic data. An intravenous epinephrine infusion should be prepared for patients with persistent anaphylaxis after 2 doses of IM/IN epinephrine and initiated after the third dose, or earlier at the provider's discretion. In settings without epinephrine infusions, repeat IM/IN epinephrine should be administered every 5 minutes, along with other ABC interventions, and the patient should be transferred quickly to a setting equipped to provide advanced resuscitative care.

OriginalsprogEngelsk
TidsskriftJournal of Allergy and Clinical Immunology: In Practice
ISSN2213-2198
DOI
StatusAccepteret/In press - 2026

Fingeraftryk

Dyk ned i forskningsemnerne om 'Anaphylaxis Clinical Care Pathway: Incorporating Intranasal Epinephrine (Adrenaline)'. Sammen danner de et unikt fingeraftryk.

Citationsformater